KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
about
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.Standard chemotherapy with cetuximab for treatment of colorectal cancerKRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumorsComputational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)Mutational analysis and clinical correlation of metastatic colorectal cancer.A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastasesDigital detection of multiple minority mutants and expression levels of multiple colorectal cancer-related genes using digital-PCR coupled with bead-arrayColorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stagesICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR.PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutationsLow percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancerColorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significanceTIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Panitumumab : leading to better overall survival in metastatic colorectal cancer?Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.Personalized treatment for patients with colorectal cancer: role of biomarkers.Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.KRAS Alleles: The Devil Is in the Detail.PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.Molecular Biomarkers for the Evaluation of Colorectal Cancer.SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
P2860
Q27852942-D4917FB1-1626-4852-8DD5-8EDAE7C028EEQ27853284-A7F4DD22-C972-4A6E-9A43-A4D28E5634F9Q28088693-900ABAED-B899-4503-BD1B-1376871C6F66Q34039936-854EAC42-9684-43F6-8A93-E29BAD5C9985Q34157801-1747837D-1C43-42B1-9E46-7D848EEEA9F8Q34598203-1560F05F-08BC-4FC9-8005-7BEDBB347FFFQ34622865-994454AD-D681-4FD5-B0EC-37FFBC82E499Q35082873-4BB5C3D3-F305-48A7-9F79-6989B4DBE19EQ35402251-01EC429C-5775-44E5-94B0-45AF2751B744Q35447750-420EDC85-D4BB-4B2A-94C1-87C69A7BCA95Q35579056-43FF8E1A-4498-4F7D-B423-45881EAE025BQ36035723-81EEB54A-E9A3-4DB0-BC50-031F52934899Q36134534-63075F5D-B213-4F66-9A99-EB5D4EB5F6B8Q36335893-28B7D68F-51D2-43AD-BBD2-329135017AA7Q36545430-6431E48F-B8A8-4A5B-83A3-C7DDAF1B220FQ36621776-9DAB5A9D-2E5C-4F75-B7E5-3FC4778C8477Q36997408-09CC91BD-A078-4365-BEE3-C8F342E92BD8Q37457496-C1E9A5C0-DF7D-4575-A063-6E1F27BF0E05Q37644878-2D7A0632-9FA1-4289-97AA-86C40065BBB0Q37708019-3FAEADCC-6444-4F39-B869-12EB0EB84AC5Q37725589-33DADC2A-8676-4B52-B233-C011F7B5B3AAQ38193195-2A24924B-FAEB-4921-B946-949C80C4B5E8Q38219290-966F4EA1-AC5E-4E71-935A-A72DCBE72E0DQ38314870-A339BEA9-7964-44C8-B61B-9C6FD745507AQ38390834-6F41292B-F062-4CE8-8E8A-2D0D37689056Q38545768-56150F55-0C8A-4CDE-8262-51E73FBBE9F3Q38600228-B839C2A4-D96E-4FD9-82A0-8D825B184759Q38953667-3162F91B-88A9-4F47-8154-0B00530E5EF2Q40341349-9BA2F8CE-E2A9-437E-A0F6-F2A599F59E22Q41594760-6ED94D1A-FC1A-4354-A5F2-16109ACF1F5EQ41664652-C354337F-47B4-42DB-8C92-E3D3778B1DC6Q42160986-FFF1C9D6-354C-4884-A589-E297F697E298Q46611154-0ABAE9F9-63DB-4E2C-A9EB-9135EC3E7081Q49163920-50752968-8C56-47A9-8701-6E06AD00D3E2Q49668169-B89457AF-87F1-4D1F-8F58-94DB9F597CA3Q49959181-27F20862-B55B-4142-912A-0C3393EE790DQ52794464-E9AD43B0-B324-48EE-B96C-9C31849DA273Q55209276-B935839B-C6E8-4FA9-A2AE-765F6D5E9680
P2860
KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
KRAS p.G13D mutation and codon ...... atic review and meta-analysis.
@en
type
label
KRAS p.G13D mutation and codon ...... atic review and meta-analysis.
@en
prefLabel
KRAS p.G13D mutation and codon ...... atic review and meta-analysis.
@en
P2093
P2860
P356
P1433
P1476
KRAS p.G13D mutation and codon ...... atic review and meta-analysis.
@en
P2093
Da-Yong Zheng
Jin-Ling Tang
Jin-Zhang Chen
Ya-Fang Huang
Zu-Yao Yang
P2860
P304
P356
10.1002/CNCR.27804
P407
P577
2012-09-12T00:00:00Z